Two prominent law firms have announced class action lawsuits against Exscientia p.l.c (NASDAQ: EXAI), urging investors who purchased securities between March 23, 2022, and February 12, 2024, to seek legal counsel before approaching deadlines.
On June 8, 2024, the Rosen Law Firm, recognized globally for representing investor rights, reiterated the importance of investors acting promptly to participate in a securities class action against Exscientia. The firm emphasizes the critical nature of the June 25, 2024, lead plaintiff deadline. According to the firm’s statement, the lawsuit addresses alleged misrepresentations and possible securities fraud by Exscientia within the specified class period.
Previously, on April 30, 2024, Gainey McKenna & Egleston, another notable law firm, announced a similar securities class action in the United States District Court for the District of New Jersey. This lawsuit was also filed on behalf of investors who acquired Exscientia securities during the same class period, echoing the concerns over purported inaccuracies in the company’s public disclosures.
Both lawsuits claim Exscientia may have provided misleading information, thereby inflating the stock’s price and causing potential financial harm to investors who purchased shares in good faith based on the company’s representations.
The lawsuits could significantly impact Exscientia, a company involved in the innovative field of AI-driven drug discovery. Investors affected by this situation are urged to consult with legal professionals to ensure their rights are adequately protected and to understand the potential outcomes of these lawsuits.
As the June 25, 2024 deadline for securing lead plaintiff status approaches, it is crucial for impacted investors to remain informed and proactive in seeking legal guidance.
Comments